Malignant pleural mesothelioma (MPM) is a seemingly uncommon tumor whose incidence has in fact increased steadily and progressively over the last 30 years. Indeed, an actual "epidemic" is expected in Europe over the next 20 years. Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MPM patients remains dramatically poor (12 to 18 months' median survival from diagnosis), although exceptional cases of long-survivors are reported in all literature series. The current review will cover the dramatic improvements in the treatment of this rare disease that have been recently achieved, as well as the promise that new, molecular-targeted therapies, such as bortezomid, mTOR ( m ammalian t arget o f r apamycin) inhibitors, and Met inhibitors, seem to offer for the next few years. With pemetrexed we now have a drug that is able to impact patient survival. Together with the newer drugs, rapidly emerging from the laboratory to be applied in the clinic, we have the hope of making further advances in the struggle against this disease.

中文翻译：

---

新药治疗晚期间皮瘤。

恶性胸膜间皮瘤（MPM）是一种看似罕见的肿瘤，其发病率实际上在过去30年中一直在稳步增长。确实，在未来的20年中，欧洲有望出现实际的“流行病”。尽管我们可以使用的诊断方法得到了毫无疑问的改进，并且可以采用新的治疗策略，但是尽管所有文献均报道了长期存活者的特殊病例，但MPM患者的预后仍然非常差（诊断后的中位生存期为12至18个月）。系列。当前的综述将涵盖最近已实现的对该罕见疾病的治疗方面的显着改善，以及新的以分子为靶标的治疗方法的承诺，例如硼替佐米，mTOR（阿帕霉素的哺乳动物tTAR）抑制剂，以及遇见抑制剂 似乎会在未来几年提供。有了培美曲塞，我们现在有了一种能够影响患者生存的药物。我们希望将新药与从实验室迅速运用于临床的新药一起，在对抗这种疾病的斗争中取得进一步进展。